ANVS
Annovis Bio IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$75.72M
P/E Ratio
—
EPS
$-1.71
Beta
1.19
52W High
$5.50
52W Low
$1.54
50-Day MA
$1.98
200-Day MA
$2.58
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Annovis Bio Inc
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -220.60% |
| Return on Assets | -106.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.62 |
| Price-to-Book | 24.90 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.54M |
| Float | $25.10M |
| % Insiders | 14.10% |
| % Institutions | 16.71% |
Historical Volatility
HV 10-Day
73.48%
HV 20-Day
72.12%
HV 30-Day
78.85%
HV 60-Day
104.59%
HV Rank
33.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.50 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026